T1	Age 2 13	52-year-old
T2	Sex 14 17	man
T3	History 25 51	30-year history of smoking
T4	Sign_symptom 79 85	nodule
E1	Sign_symptom:T4 
T5	Detailed_description 70 78	abnormal
R1	MODIFY Arg1:T5 Arg2:E1	
T6	Area 96 108	0.8 × 1.5 cm
R2	MODIFY Arg1:T6 Arg2:E1	
T7	Biological_structure 116 136	left upper lung lobe
R3	MODIFY Arg1:T7 Arg2:E1	
T8	Diagnostic_procedure 158 177	computed tomography
E2	Diagnostic_procedure:T8 
T9	Biological_structure 152 157	chest
R4	MODIFY Arg1:T9 Arg2:E2	
T10	Diagnostic_procedure 179 181	CT
E3	Diagnostic_procedure:T10 
R5	IDENTICAL Arg1:E3 Arg2:E2	
T11	Date 195 205	March 2012
E4	Date:T11 
T12	Nonbiological_location 211 229	community hospital
T13	Clinical_event 52 61	presented
E5	Clinical_event:T13 
R6	MODIFY Arg1:T12 Arg2:E5	
T14	History 238 311	previously been well without any additional relevant or abnormal symptoms
T15	Diagnostic_procedure 313 333	Physical examination
E6	Diagnostic_procedure:T15 
T16	Sign_symptom 359 372	abnormalities
E7	Sign_symptom:T16 
A1	POLARITY E7 NEG
T17	Diagnostic_procedure 374 393	Laboratory findings
E8	Diagnostic_procedure:T17 
T18	Lab_value 399 418	within normal range
R7	MODIFY Arg1:T18 Arg2:E8	
T19	Diagnostic_procedure 433 457	carcinoembryonic antigen
E9	Diagnostic_procedure:T19 
T20	Diagnostic_procedure 459 462	CEA
E10	Diagnostic_procedure:T20 
R8	IDENTICAL Arg1:E10 Arg2:E9	
R9	SUB_PROCEDURE Arg1:E9 Arg2:E8	
T21	Lab_value 473 484	30.25 ng/mL
R10	MODIFY Arg1:T21 Arg2:E9	
T22	Biological_structure 524 529	serum
R11	MODIFY Arg1:T22 Arg2:T21	
T23	Diagnostic_procedure 547 575	positron emission tomography
E11	Diagnostic_procedure:T23 
T24	Diagnostic_procedure 577 580	PET
E12	Diagnostic_procedure:T24 
R12	IDENTICAL Arg1:E12 Arg2:E11	
T25	Diagnostic_procedure 582 584	CT
E13	Diagnostic_procedure:T25 
T26	Sign_symptom 604 610	lesion
E14	Sign_symptom:T26 
T27	Biological_structure 599 603	lung
R13	MODIFY Arg1:T27 Arg2:E14	
T28	Diagnostic_procedure 618 643	standardized uptake value
E15	Diagnostic_procedure:T28 
T29	Lab_value 647 651	7.94
R14	MODIFY Arg1:T29 Arg2:E15	
R15	MODIFY Arg1:E14 Arg2:E15	
T30	Disease_disorder 688 703	malignant tumor
E16	Disease_disorder:T30 
T31	Therapeutic_procedure 756 765	lobectomy
E17	Therapeutic_procedure:T31 
T32	Biological_structure 740 755	left upper lung
R16	MODIFY Arg1:T32 Arg2:E17	
T33	Therapeutic_procedure 770 791	lymph node dissection
E18	Therapeutic_procedure:T33 
T34	Diagnostic_procedure 807 831	pathological examination
E19	Diagnostic_procedure:T34 
T35	Disease_disorder 844 858	adenocarcinoma
E20	Disease_disorder:T35 
T36	Disease_disorder 860 863	ADC
E21	Disease_disorder:T36 
R17	IDENTICAL Arg1:E21 Arg2:E20	
T37	Diagnostic_procedure 875 895	Immunohistochemistry
E22	Diagnostic_procedure:T37 
T38	Diagnostic_procedure 897 900	IHC
E23	Diagnostic_procedure:T38 
R18	IDENTICAL Arg1:E23 Arg2:E22	
T39	Diagnostic_procedure 937 940	CK7
E24	Diagnostic_procedure:T39 
T40	Diagnostic_procedure 942 947	TTF-1
E25	Diagnostic_procedure:T40 
T41	Diagnostic_procedure 949 952	p63
E26	Diagnostic_procedure:T41 
T42	Diagnostic_procedure 958 965	NapsinA
E27	Diagnostic_procedure:T42 
T43	Diagnostic_procedure 983 989	CK 5/6
E28	Diagnostic_procedure:T43 
T44	Diagnostic_procedure 991 994	Syn
E29	Diagnostic_procedure:T44 
T45	Diagnostic_procedure 996 999	cgA
E30	Diagnostic_procedure:T45 
T46	Diagnostic_procedure 1005 1010	Ki-67
E31	Diagnostic_procedure:T46 
T47	Lab_value 970 978	negative
R19	MODIFY Arg1:T47 Arg2:E28	
R20	MODIFY Arg1:T47 Arg2:E29	
R21	MODIFY Arg1:T47 Arg2:E30	
R22	MODIFY Arg1:T47 Arg2:E31	
T48	Lab_value 924 932	positive
R23	MODIFY Arg1:T48 Arg2:E24	
R24	MODIFY Arg1:T48 Arg2:E25	
R25	MODIFY Arg1:T48 Arg2:E26	
R26	SUB_PROCEDURE Arg1:E24 Arg2:E22	
R27	SUB_PROCEDURE Arg1:E25 Arg2:E22	
R28	SUB_PROCEDURE Arg1:E26 Arg2:E22	
R29	SUB_PROCEDURE Arg1:E27 Arg2:E22	
R30	SUB_PROCEDURE Arg1:E28 Arg2:E22	
R31	SUB_PROCEDURE Arg1:E29 Arg2:E22	
R32	SUB_PROCEDURE Arg1:E30 Arg2:E22	
R33	SUB_PROCEDURE Arg1:E31 Arg2:E22	
T49	Diagnostic_procedure 1026 1040	clinical stage
E32	Diagnostic_procedure:T49 
T50	Lab_value 1059 1062	IA2
R34	MODIFY Arg1:T50 Arg2:E32	
T51	Lab_value 1064 1072	pT1bN0M0
R35	MODIFY Arg1:T51 Arg2:E32	
T52	Coreference 1087 1092	tumor
E33	Coreference:T52 
R36	IDENTICAL Arg1:E33 Arg2:E14	
T53	Medication 1150 1168	adjuvant treatment
E34	Medication:T53 
A2	POLARITY E34 NEG
T54	Detailed_description 1109 1120	early stage
R37	MODIFY Arg1:T54 Arg2:E33	
T55	Therapeutic_procedure 1189 1198	monitored
E35	Therapeutic_procedure:T55 
T56	Clinical_event 1224 1230	visits
E36	Clinical_event:T56 
T57	Frequency 1231 1245	every 3 months
R38	MODIFY Arg1:T57 Arg2:E36	
T58	Nonbiological_location 1215 1223	hospital
R39	MODIFY Arg1:T58 Arg2:E36	
T59	Diagnostic_procedure 1261 1270	condition
E37	Diagnostic_procedure:T59 
T60	Lab_value 1280 1286	stable
R40	MODIFY Arg1:T60 Arg2:E37	
T61	Sign_symptom 1317 1321	pain
E38	Sign_symptom:T61 
T62	Biological_structure 1306 1316	left chest
R41	MODIFY Arg1:T62 Arg2:E38	
T63	Date 1325 1335	April 2015
E39	Date:T63 
T64	Clinical_event 1353 1364	transferred
E40	Clinical_event:T64 
T65	Nonbiological_location 1372 1380	hospital
T66	Nonbiological_location 1384 1406	tertiary care hospital
R42	MODIFY Arg1:T65 Arg2:E40	
R43	MODIFY Arg1:T66 Arg2:E40	
T67	Diagnostic_procedure 1431 1451	Physical examination
E41	Diagnostic_procedure:T67 
T68	Sign_symptom 1476 1488	tender point
E42	Sign_symptom:T68 
T69	Biological_structure 1496 1511	left chest wall
R44	MODIFY Arg1:T69 Arg2:E42	
T70	Severity 1464 1475	significant
R45	MODIFY Arg1:T70 Arg2:E42	
T71	Diagnostic_procedure 1513 1532	Laboratory findings
E43	Diagnostic_procedure:T71 
T72	Diagnostic_procedure 1594 1629	cytokeratin19 fragment antigen 21–1
E44	Diagnostic_procedure:T72 
T73	Diagnostic_procedure 1631 1640	CYFRA21–1
E45	Diagnostic_procedure:T73 
R46	IDENTICAL Arg1:E45 Arg2:E44	
T74	Lab_value 1652 1663	17.45 ng/mL
T75	Biological_structure 1671 1676	serum
R47	MODIFY Arg1:T75 Arg2:T74	
R48	MODIFY Arg1:T74 Arg2:E44	
R49	SUB_PROCEDURE Arg1:E44 Arg2:E43	
T76	Diagnostic_procedure 1707 1709	CT
E46	Diagnostic_procedure:T76 
T77	Diagnostic_procedure 1714 1717	PET
E47	Diagnostic_procedure:T77 
T78	Diagnostic_procedure 1718 1720	CT
E48	Diagnostic_procedure:T78 
T79	Sign_symptom 1751 1762	involvement
E49	Sign_symptom:T79 
T80	Severity 1743 1750	serious
R50	MODIFY Arg1:T80 Arg2:E49	
T81	Biological_structure 1766 1777	left pleura
R51	MODIFY Arg1:T81 Arg2:E49	
T82	Sign_symptom 1802 1809	lesions
E50	Sign_symptom:T82 
T83	Biological_structure 1797 1801	lung
T84	Detailed_description 1787 1796	bilateral
R52	MODIFY Arg1:T84 Arg2:E50	
R53	MODIFY Arg1:T83 Arg2:E50	
T85	Diagnostic_procedure 1845 1859	clinical stage
E51	Diagnostic_procedure:T85 
T86	Lab_value 1864 1872	upgraded
T87	Lab_value 1876 1879	IVB
R54	MODIFY Arg1:T86 Arg2:E51	
R55	MODIFY Arg1:T87 Arg2:E51	
T88	Therapeutic_procedure 1913 1921	puncture
E52	Therapeutic_procedure:T88 
T89	Biological_structure 1901 1912	left pleura
T90	Detailed_description 1891 1900	CT-guided
R56	MODIFY Arg1:T89 Arg2:E52	
R57	MODIFY Arg1:T90 Arg2:E52	
T91	Diagnostic_procedure 1936 1948	IHC analysis
E53	Diagnostic_procedure:T91 
T92	Diagnostic_procedure 1978 1981	p63
E54	Diagnostic_procedure:T92 
T93	Diagnostic_procedure 1983 1986	p40
E55	Diagnostic_procedure:T93 
T94	Diagnostic_procedure 1988 1992	CK 7
E56	Diagnostic_procedure:T94 
T95	Diagnostic_procedure 1998 2004	CK 5/6
E57	Diagnostic_procedure:T95 
T96	Diagnostic_procedure 2012 2017	TTF-1
E58	Diagnostic_procedure:T96 
T97	Diagnostic_procedure 2022 2029	NapsinA
E59	Diagnostic_procedure:T97 
T98	Disease_disorder 2078 2101	squamous cell carcinoma
E60	Disease_disorder:T98 
T99	Disease_disorder 2103 2106	SCC
E61	Disease_disorder:T99 
R58	IDENTICAL Arg1:E61 Arg2:E60	
T100	Lab_value 1956 1964	positive
R59	MODIFY Arg1:T100 Arg2:E54	
R60	MODIFY Arg1:T100 Arg2:E55	
R61	MODIFY Arg1:T100 Arg2:E56	
R62	MODIFY Arg1:T100 Arg2:E57	
T101	Lab_value 2044 2050	absent
R63	MODIFY Arg1:T101 Arg2:E59	
R64	MODIFY Arg1:T101 Arg2:E58	
R65	SUB_PROCEDURE Arg1:E54 Arg2:E53	
R66	SUB_PROCEDURE Arg1:E55 Arg2:E53	
R67	SUB_PROCEDURE Arg1:E56 Arg2:E53	
R68	SUB_PROCEDURE Arg1:E57 Arg2:E53	
R69	SUB_PROCEDURE Arg1:E58 Arg2:E53	
R70	SUB_PROCEDURE Arg1:E59 Arg2:E53	
T102	Diagnostic_procedure 2129 2149	molecular evaluation
E62	Diagnostic_procedure:T102 
T103	Sign_symptom 2163 2177	L858R mutation
E63	Sign_symptom:T103 
T104	Sign_symptom 2195 2209	T790M mutation
E64	Sign_symptom:T104 
T105	Detailed_description 2213 2220	exon 20
T106	Detailed_description 2181 2188	exon 21
R71	MODIFY Arg1:T106 Arg2:E63	
R72	MODIFY Arg1:T105 Arg2:E64	
T107	Other_entity 2237 2437	Considering the pathology of the SCC was quite distinct compared with that of the originally resected NSCLC specimen, we retrospectively reassessed the surgery specimen to verify our primary diagnosis
#1	AnnotatorNotes T107	Discussion
T108	Other_entity 2439 2605	The morphologic and IHC results were in complete agreement with the initial diagnoses, but an L858R mutation was identified using the newly added molecular evaluation
#2	AnnotatorNotes T108	Discussion
T109	Therapeutic_procedure 2696 2736	three-dimensional conformal radiotherapy
E65	Therapeutic_procedure:T109 
T110	Therapeutic_procedure 2738 2744	3D-CRT
E66	Therapeutic_procedure:T110 
R73	IDENTICAL Arg1:E66 Arg2:E65	
T111	Detailed_description 2685 2695	palliative
R74	MODIFY Arg1:T111 Arg2:E65	
T112	Dosage 2800 2818	42 Gy/14 fractions
R75	MODIFY Arg1:T112 Arg2:E65	
T113	Frequency 2824 2834	once daily
T114	Dosage 2839 2846	5f/week
R76	MODIFY Arg1:T113 Arg2:T112	
R77	MODIFY Arg1:T114 Arg2:E65	
T115	Sign_symptom 2760 2766	lesion
E67	Sign_symptom:T115 
T116	Biological_structure 2754 2759	chest
R78	MODIFY Arg1:T116 Arg2:E67	
T117	Medication 3510 3519	gefitinib
E68	Medication:T117 
T118	Dosage 3521 3530	150 mg qd
R79	MODIFY Arg1:T118 Arg2:E68	
T119	Date 3566 3584	from November 2015
E69	Date:T119 
T120	Medication 3615 3633	Ibandronate sodium
E70	Medication:T120 
T121	Frequency 3644 3651	monthly
R80	MODIFY Arg1:T121 Arg2:E70	
T122	Sign_symptom 3656 3679	skeletal-related events
E71	Sign_symptom:T122 
T123	Diagnostic_procedure 3730 3732	SD
E72	Diagnostic_procedure:T123 
T124	Diagnostic_procedure 3757 3759	PS
E73	Diagnostic_procedure:T124 
T125	Lab_value 3770 3771	0
R81	MODIFY Arg1:T125 Arg2:E73	
R82	MODIFY Arg1:T125 Arg2:E72	
T126	Clinical_event 3706 3724	under surveillance
E74	Clinical_event:T126 
T127	Diagnostic_procedure 2860 2891	volume over radiation dose 5 Gy
E75	Diagnostic_procedure:T127 
T128	Lab_value 2945 2948	20%
T129	Lab_value 2950 2952	0%
T130	Lab_value 2958 2962	7.8%
T131	Biological_structure 2911 2915	left
T132	Biological_structure 2917 2922	right
T133	Biological_structure 2928 2939	total lungs
R83	MODIFY Arg1:T131 Arg2:T128	
R84	MODIFY Arg1:T132 Arg2:T129	
R85	MODIFY Arg1:T133 Arg2:T130	
R86	MODIFY Arg1:T128 Arg2:E75	
R87	MODIFY Arg1:T129 Arg2:E75	
R88	MODIFY Arg1:T130 Arg2:E75	
T134	Diagnostic_procedure 2982 3014	volume over radiation dose 20 Gy
E76	Diagnostic_procedure:T134 
T135	Lab_value 3033 3036	10%
T136	Lab_value 3038 3040	0%
T137	Lab_value 3046 3048	5%
R89	MODIFY Arg1:T135 Arg2:E76	
R90	MODIFY Arg1:T136 Arg2:E76	
R91	MODIFY Arg1:T137 Arg2:E76	
T138	Diagnostic_procedure 3068 3082	mean lung dose
E77	Diagnostic_procedure:T138 
T139	Lab_value 3093 3097	5 Gy
R92	MODIFY Arg1:T139 Arg2:E77	
T140	Diagnostic_procedure 3084 3087	MLD
E78	Diagnostic_procedure:T140 
R93	IDENTICAL Arg1:E78 Arg2:E77	
T141	Medication 3178 3193	GP chemotherapy
E79	Medication:T141 
T142	Medication 3195 3204	cisplatin
E80	Medication:T142 
T143	Medication 3218 3229	gemcitabine
E81	Medication:T143 
T144	Dosage 3205 3216	75 mg/m2 d1
T145	Dosage 3230 3247	1250 mg/m2 d1, d8
R94	MODIFY Arg1:T144 Arg2:E80	
R95	MODIFY Arg1:T145 Arg2:E81	
T146	Lab_value 3277 3285	4 cycles
R96	MODIFY Arg1:T146 Arg2:E79	
R97	SUB_PROCEDURE Arg1:E80 Arg2:E79	
R98	SUB_PROCEDURE Arg1:E81 Arg2:E79	
T147	Detailed_description 3253 3271	21 days as a cycle
R99	MODIFY Arg1:T147 Arg2:T146	
T148	Sign_symptom 3320 3329	remission
E82	Sign_symptom:T148 
A3	POLARITY E82 MAYBE_POS
T149	Detailed_description 3312 3319	partial
R100	MODIFY Arg1:T149 Arg2:E82	
T150	Date 3335 3349	after 2 cycles
E83	Date:T150 
T151	Disease_disorder 3363 3377	stable disease
E84	Disease_disorder:T151 
T152	Disease_disorder 3379 3381	SD
E85	Disease_disorder:T152 
R101	IDENTICAL Arg1:E85 Arg2:E84	
T153	Date 3383 3397	after 4 cycles
E86	Date:T153 
T154	Diagnostic_procedure 3445 3489	response evaluation criteria in solid tumors
E87	Diagnostic_procedure:T154 
T155	Diagnostic_procedure 3491 3497	RECIST
E88	Diagnostic_procedure:T155 
R102	IDENTICAL Arg1:E88 Arg2:E87	
T156	Detailed_description 3499 3502	1.1
R103	MODIFY Arg1:T156 Arg2:E87	
*	OVERLAP E5 E1 E2 E4 E6 E8 E11 E13 E14 E15 E16
R104	BEFORE Arg1:E16 Arg2:E17	
*	OVERLAP E17 E18
R105	BEFORE Arg1:E18 Arg2:E19	
*	OVERLAP E19 E20 E22 E32
R106	BEFORE Arg1:E32 Arg2:E33	
*	OVERLAP E33 E34 E35 E36
R107	BEFORE Arg1:E36 Arg2:E37	
R108	BEFORE Arg1:E37 Arg2:E38	
*	OVERLAP E38 E39
R109	BEFORE Arg1:E39 Arg2:E40	
*	OVERLAP E40 E41 E42 E43 E46 E47 E48 E49 E50 E51
R110	BEFORE Arg1:E51 Arg2:E52	
R111	BEFORE Arg1:E52 Arg2:E53	
*	OVERLAP E53 E60 E62 E63 E64
R112	BEFORE Arg1:E64 Arg2:E65	
*	OVERLAP E65 E67 E75 E76 E77 E79
R113	BEFORE Arg1:E79 Arg2:E82	
*	OVERLAP E82 E83
R114	BEFORE Arg1:E83 Arg2:E84	
*	OVERLAP E84 E86 E87
R115	BEFORE Arg1:E87 Arg2:E68	
*	OVERLAP E68 E69 E70 E71
R116	BEFORE Arg1:E71 Arg2:E74	
*	OVERLAP E74 E72 E73
